Migraine Minute News Update Association of Migraine Disorders

A new study looks at real-word effectiveness of Anti-CGRP monoclonal antibodies & OnabotulinumtoxinA for chronic migraine. Molly O'Brien will share the study findings in this Migraine Minute News update. Read the study: https://bit.ly/4d1mPx1

*The graphic used in this content is courtesy of Grazzi, L., Giossi, R., Montisano, D.A. et al. Real-world effectiveness of Anti-CGRP monoclonal antibodies compared to OnabotulinumtoxinA (RAMO) in chronic migraine: a retrospective, observational, multicenter, cohort study. J Headache Pain 25, 14 (2024). https://doi.org/10.1186/s10194-024-01721-6. The graphical abstract has been slightly modified.

 Researchers at the University of California Los Angeles found changes in blood flow in the retina might explain why some people have visual migraine symptoms. Molly O'Brien has the details in this Migraine Minute News update. 
Learn more: https://bit.ly/3xou7uw , https://bit.ly/4aErYZN

AMD is thrilled to share what we’ve learned so far from our HEADS Registry!

Molly O'Brien goes over the exclusive new data in this Migraine Minute News Update.

The HEADS Registry serves as a crucial resource for researchers and clinicians. It’s not too late to share your experience, by doing so, you can help pave the way for more effective therapies, enhanced and personalized patient care, and improved quality of life.

Learn more at migrainedisorders.org/heads-registry/

Obesity is often connected with an increase in migraine frequency, severity and disability.
In this Migraine Minute News Update, Molly O'Brien gives details on what we’re learning about one MAB drug and its effectiveness in people with migraine and comorbid obesity.
 
Read more here: https://bit.ly/3ONRu6m
 

New results from the OVERCOME study, published in Neurology,  Found that just over 31 percent of people living with migraine often or very often feel stigmatized. Molly O'Brien will fill you in on the details in this Migraine Minute News Update. 

Nerivio becomes the first drug-free Migraine Treatment to Receive Commercial Insurance Coverage in the US. Molly O'Brien explains in this Migraine Minute News Update.

Read more here: https://bit.ly/3T6lKvL